HighPoint Advisor Group LLC Raises Stake in Medpace Holdings, Inc. (NASDAQ:MEDP)

HighPoint Advisor Group LLC lifted its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 24.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 795 shares of the company’s stock after acquiring an additional 158 shares during the period. HighPoint Advisor Group LLC’s holdings in Medpace were worth $261,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of MEDP. Vanguard Group Inc. raised its stake in Medpace by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 2,570,770 shares of the company’s stock worth $854,087,000 after purchasing an additional 25,704 shares during the period. State Street Corp raised its position in shares of Medpace by 7.2% during the 3rd quarter. State Street Corp now owns 752,957 shares of the company’s stock valued at $251,337,000 after buying an additional 50,312 shares during the period. Geode Capital Management LLC lifted its holdings in Medpace by 7.6% in the third quarter. Geode Capital Management LLC now owns 628,054 shares of the company’s stock valued at $209,885,000 after acquiring an additional 44,371 shares during the last quarter. Wellington Management Group LLP grew its position in Medpace by 36.0% in the third quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock worth $138,612,000 after acquiring an additional 109,886 shares during the period. Finally, GW&K Investment Management LLC increased its stake in Medpace by 93.9% during the fourth quarter. GW&K Investment Management LLC now owns 275,460 shares of the company’s stock worth $91,516,000 after acquiring an additional 133,379 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Stock Performance

NASDAQ MEDP opened at $304.11 on Friday. The firm has a market cap of $9.27 billion, a price-to-earnings ratio of 24.08, a PEG ratio of 3.81 and a beta of 1.45. The firm has a 50 day simple moving average of $332.70 and a 200-day simple moving average of $338.09. Medpace Holdings, Inc. has a one year low of $289.01 and a one year high of $459.77.

Medpace (NASDAQ:MEDP – Get Free Report) last posted its quarterly earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. Equities analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on MEDP shares. Robert W. Baird upped their price target on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. Leerink Partnrs raised shares of Medpace to a “hold” rating in a research report on Monday, March 24th. Finally, Leerink Partners started coverage on shares of Medpace in a research report on Monday, March 24th. They set a “market perform” rating and a $330.00 price target for the company. Nine research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $376.30.

Get Our Latest Research Report on MEDP

About Medpace

(Free Report)

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

See Also

• Five stocks we like better than Medpace
• Stock Market Upgrades: What Are They?
• Shares of RH Down Nearly 40%: Where Investors Can Turn To Now
• Why Are Stock Sectors Important to Successful Investing?
• Tariffs, Spin-Out, and R2 Updates Are Positive Signs for Rivian
• When to Sell a Stock for Profit or Loss
• Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy?

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).